Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Staphylococcal Skin Infections01:29

Staphylococcal Skin Infections

Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...
Defense Against Bacterial Pathogens01:31

Defense Against Bacterial Pathogens

The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Antimicrobial Proteins01:23

Antimicrobial Proteins

Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>Staphylococcus aureus</i> transcriptomics and single-cell sequencing approaches.

Infection and immunity·2025
Same author

Evaluation of capsule polysaccharide (CPS)-specific antibodies for broad recognition of prominent multidrug-resistant <i>Klebsiella pneumoniae</i>.

Microbiology spectrum·2025
Same author

<i>Staphylococcus aureus</i> SaeR/S-regulated factors overcome human complement-mediated inhibition of aggregation to evade neutrophil killing.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Carbapenem-Resistant, Virulence Plasmid-Harboring Klebsiella pneumoniae, United States.

Emerging infectious diseases·2025
Same author

Insights into the molecular basis of reduced vancomycin susceptibility among three prominent <i>Staphylococcus aureus</i> clonal complexes.

Microbiology spectrum·2024
Same author

Interaction of multidrug-resistant hypervirulent <i>Klebsiella pneumoniae</i> with components of human innate host defense.

mBio·2023

Related Experiment Video

Updated: May 7, 2026

A Mouse Model to Assess Innate Immune Response to Staphylococcus aureus Infection
09:15

A Mouse Model to Assess Innate Immune Response to Staphylococcus aureus Infection

Published on: February 28, 2019

Staphylococcus aureus protein A promotes immune suppression.

Scott D Kobayashi1, Frank R DeLeo

  • 1Laboratory of Human Bacterial Pathogenesis, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.

Mbio
|October 3, 2013
PubMed
Summary

Developing a vaccine against Staphylococcus aureus (S. aureus) is crucial due to rising antibiotic resistance. A study found that removing protein A (SpA) from S. aureus enhances vaccine efficacy against infections.

More Related Videos

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)
12:18

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)

Published on: February 9, 2011

Quantifying the Cytotoxicity of Staphylococcus aureus Against Human Polymorphonuclear Leukocytes
12:27

Quantifying the Cytotoxicity of Staphylococcus aureus Against Human Polymorphonuclear Leukocytes

Published on: January 3, 2020

Related Experiment Videos

Last Updated: May 7, 2026

A Mouse Model to Assess Innate Immune Response to Staphylococcus aureus Infection
09:15

A Mouse Model to Assess Innate Immune Response to Staphylococcus aureus Infection

Published on: February 28, 2019

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)
12:18

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)

Published on: February 9, 2011

Quantifying the Cytotoxicity of Staphylococcus aureus Against Human Polymorphonuclear Leukocytes
12:27

Quantifying the Cytotoxicity of Staphylococcus aureus Against Human Polymorphonuclear Leukocytes

Published on: January 3, 2020

Area of Science:

  • Microbiology
  • Immunology
  • Vaccinology

Background:

  • Staphylococcus aureus, particularly methicillin-resistant MRSA, causes significant global infections.
  • Limited treatment options for severe MRSA infections necessitate vaccine development.
  • Previous vaccine attempts failed despite in vitro and animal model success, suggesting immune evasion strategies by S. aureus.

Purpose of the Study:

  • To investigate the role of Staphylococcus aureus protein A (SpA) in immune evasion.
  • To evaluate the efficacy of SpA-deficient S. aureus strains in vaccine development.

Main Methods:

  • Vaccination of mice with spa mutant S. aureus strains lacking SpA's antibody-binding capabilities.
  • Subsequent challenge with the epidemic USA300 S. aureus strain to assess protection.

Main Results:

  • Vaccination with spa mutant strains lacking Fc- and Fab-binding capacity conferred protection against USA300 challenge.
  • This indicates that SpA actively promotes S. aureus immune evasion in vivo.

Conclusions:

  • Protein A (SpA) is a key factor in Staphylococcus aureus immune evasion.
  • Targeting SpA offers a promising new strategy for developing effective S. aureus vaccines.